Foxy 5 peptide

Foxy 5 peptide

• Handling and Storage of Synthetic Peptides
• Material Safety Data Sheets (MSDS)

Formylation-MDGCEL-OH

Formylation-Met-Asp-Gly-Cys-Glu-Leu-OH

6

95.04%

C₂₆H₄₂N₆O₁₂S₂

694.77

Synthetic

Powder

Foxy 5 is a formylated hexapeptide derived from the sequence of the Wnt5a ligand which acts as a Wnt5a mimetic. Foxy 5 is able to mimic important effects exerted by the full Wnt5a molecule such as binding to the Frz-5 receptor, and reproducing Wnt5a induced inhibition of human breast cancer cell migration in vitro. Foxy 5 significantly reduces the metastatic spread of WNT5a low DU145 prostate cancer cells in an in vivo orthotopic xenograft mouse model.

Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual:Handling and Storage of Synthetic Peptides

• Säfholm et al (2006) A formylated hexapeptide ligand mimics the ability of Wnt-5a to impair migration of human breast epithelial cells. J.Biol.Chem. 281 2740 PMID: 16330545
• Säfholm et al (2008) The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin.Cancer Res. 14 6556 PMID: 18927296
• Canesin (2017) Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS One 12(9) e0184418 PMID: 28886116

Trifluoroacetic acid (TFA) has a significant impact on peptides due to its role in the peptide synthesis process.

TFA is essential for the protonation of peptides that lack basic amino acids such as Arginine (Arg), Histidine (His), and Lysine (Lys), or ones that have blocked N-termini. As a result, peptides often contain TFA salts in the final product.

TFA residues, when present in custom peptides, can cause unpredictable fluctuations in experimental data. At a nanomolar (nM) level, TFA can influence cell experiments, hindering cell growth at low concentrations (as low as 10 nM) and promoting it at higher doses (0.5–7.0 mM). It can also serve as an allosteric regulator on the GlyR of glycine receptors, thereby increasing receptor activity at lower glycine concentrations.

In an in vivo setting, TFA can trifluoroacetylate amino groups in proteins and phospholipids, inducing potentially unwanted antibody responses. Moreover, TFA can impact structure studies as it affects spectrum absorption.